Search research articles
Contact Us
Filters
Showing results (1-10 of 23) with videos related to
Page
of 3
Sort By:
Pathology, Research and Practice
|
September 16, 2021
Can evaluation of mismatch repair defect and TILs increase the number of triple-negative breast cancer patients eligible for immunotherapy?
Demet Özcan, Johanne Lade-Keller, Trine Tramm
Human Pathology
|
June 21, 2021
Frequently used quantitative polymerase chain reaction-based methods overlook potential clinically relevant genetic alterations in epidermal growth factor receptor compared with next-generation sequencing: a retrospective clinical comparison of 1839 lung adenocarcinomas
Ea Tønnesen, Johanne Lade-Keller, Magnus Stougaard
Journal of Clinical Pathology
|
November 21, 2022
Prognostic value of <i>KRAS</i> mutations, <i>TP53</i> mutations and PD-L1 expression among lung adenocarcinomas treated with immunotherapy
Ea Maria Tønning Tønnesen, Magnus Stougaard, Peter Meldgaard, et al.
Melanoma Research
|
March 24, 2018
Telomerase reverse transcriptase promoter mutations and solar elastosis in cutaneous melanoma
Johanne Lade-Keller, Sakineh Yuusufi, Rikke Riber-Hansen, et al.
The Journal of Investigative Dermatology
|
September 2, 2014
KIT is a frequent target for epigenetic silencing in cutaneous melanoma
Christina Dahl, Cecilie Abildgaard, Rikke Riber-Hansen, et al.
Experimental and Molecular Pathology
|
January 30, 2022
A targeted expression panel for classification, gene fusion detection and PD-L1 measurements - Can molecular profiling replace immunohistochemistry in non-small cell lung cancer?
Anita Tranberg Simonsen, Amalie Utke, Johanne Lade-Keller, et al.
Journal of Clinical Pathology
|
March 11, 2014
Immunohistochemical analysis of molecular drivers in melanoma identifies p16 as an independent prognostic biomarker
Johanne Lade-Keller, Rikke Riber-Hansen, Per Guldberg, et al.
Histopathology
|
November 10, 2017
Concordance in BRAF V600E status over time in malignant melanoma and corresponding metastases
Line B Nielsen, Nina Dabrosin, Karen Sloth, et al.
The Journal of Molecular Diagnostics : JMD
|
August 20, 2013
Author's reply: To PMID 23159593
Lasse S Kristensen, Lise Lotte Hansen, Johanne Lade-Keller, et al.
Ugeskrift for Laeger
|
April 2, 2025
[Melanoma]
Mette Mogensen, Terese von Knorring, Lisbet Rosenkrantz Hölmich, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 23) with videos related to
Sort By:
Page
of 3
Pathology, Research and Practice
|
September 16, 2021
Can evaluation of mismatch repair defect and TILs increase the number of triple-negative breast cancer patients eligible for immunotherapy?
Demet Özcan, Johanne Lade-Keller, Trine Tramm
Human Pathology
|
June 21, 2021
Frequently used quantitative polymerase chain reaction-based methods overlook potential clinically relevant genetic alterations in epidermal growth factor receptor compared with next-generation sequencing: a retrospective clinical comparison of 1839 lung adenocarcinomas
Ea Tønnesen, Johanne Lade-Keller, Magnus Stougaard
Journal of Clinical Pathology
|
November 21, 2022
Prognostic value of <i>KRAS</i> mutations, <i>TP53</i> mutations and PD-L1 expression among lung adenocarcinomas treated with immunotherapy
Ea Maria Tønning Tønnesen, Magnus Stougaard, Peter Meldgaard, et al.
Melanoma Research
|
March 24, 2018
Telomerase reverse transcriptase promoter mutations and solar elastosis in cutaneous melanoma
Johanne Lade-Keller, Sakineh Yuusufi, Rikke Riber-Hansen, et al.
The Journal of Investigative Dermatology
|
September 2, 2014
KIT is a frequent target for epigenetic silencing in cutaneous melanoma
Christina Dahl, Cecilie Abildgaard, Rikke Riber-Hansen, et al.
Experimental and Molecular Pathology
|
January 30, 2022
A targeted expression panel for classification, gene fusion detection and PD-L1 measurements - Can molecular profiling replace immunohistochemistry in non-small cell lung cancer?
Anita Tranberg Simonsen, Amalie Utke, Johanne Lade-Keller, et al.
Journal of Clinical Pathology
|
March 11, 2014
Immunohistochemical analysis of molecular drivers in melanoma identifies p16 as an independent prognostic biomarker
Johanne Lade-Keller, Rikke Riber-Hansen, Per Guldberg, et al.
Histopathology
|
November 10, 2017
Concordance in BRAF V600E status over time in malignant melanoma and corresponding metastases
Line B Nielsen, Nina Dabrosin, Karen Sloth, et al.
The Journal of Molecular Diagnostics : JMD
|
August 20, 2013
Author's reply: To PMID 23159593
Lasse S Kristensen, Lise Lotte Hansen, Johanne Lade-Keller, et al.
Ugeskrift for Laeger
|
April 2, 2025
[Melanoma]
Mette Mogensen, Terese von Knorring, Lisbet Rosenkrantz Hölmich, et al.
Page
of 3